Follicular lymphoma: evolving therapeutic strategies

被引:125
作者
Kahl, Brad S. [1 ]
Yang, David T. [2 ]
机构
[1] Washington Univ, Sch Med, Div Oncol, 660 South Euclid Ave,Campus Box 8056, St Louis, MO 63110 USA
[2] Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI USA
关键词
NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; STEM-CELL TRANSPLANTATION; DETUDE DES LYMPHOMES; ADVANCED-STAGE; OPEN-LABEL; INDEPENDENT PREDICTOR; 1ST-LINE TREATMENT; PROGNOSTIC VALUE; VARIABLE-REGION;
D O I
10.1182/blood-2015-11-624288
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Follicular lymphoma (FL) is the most commonindolent non-Hodgkin lymphoma in the Western hemisphere. After decades of stagnation, the natural history of FL appears to have been favorably impacted by the introduction of rituximab. Randomized clinical trials have demonstrated that the addition of rituximab to standard chemotherapy induction has improved the overall survival. Maintenance rituximab strategies can improve progression free survival. Even chemotherapy platforms have changed in the past 5 years, as bendamustine combined with rituximab has rapidly become a standard frontline strategy in North America and parts of Europe. Recent discoveries have identified patients at high risk for poor outcomes to first-line therapy (m7-Follicular Lymphoma International Prognostic Index [m7-FLIPI]) and for poor outcomes after frontline therapy (National LymphoCare Study). However, several un-met needs remain, including a better ability to identify high-risk patients at diagnosis, the development of predictive biomarkers for targeted agents, and strategies to reduce the risk of transformation. The development of targeted agents, exploiting our current understanding of FL biology, is a high research priority. A multitude of novel therapies are under investigation in both the frontline and relapsed/refractory settings. It will be critical to identify the most appropriate populations for new agents and to develop validated surrogate end points, so that novel agents can be tested (and adopted, if appropriate) efficiently.
引用
收藏
页码:2055 / 2063
页数:9
相关论文
共 81 条
[1]   Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy [J].
Advani, R ;
Rosenberg, SA ;
Horning, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1454-1459
[2]  
Advani RH, 2015, J CLIN ONCOL S, V33
[3]   Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma [J].
Al-Tourah, Abdulwahab J. ;
Gill, Karamjit K. ;
Chhanabhai, Mukesh ;
Hoskins, Paul J. ;
Klasa, Richard J. ;
Savage, Kerry J. ;
Sehn, Laurie H. ;
Shenkier, Tamara N. ;
Gascoyne, Randy D. ;
Connors, Joseph M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5165-5169
[4]   Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients [J].
Alvaro, Tomas ;
Lejeune, Marylene ;
Salvado, Maria-Teresa ;
Lopez, Carlos ;
Jaen, Joaquin ;
Bosch, Ramon ;
Pons, Lluis E. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5350-5357
[5]   DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma [J].
Amin, Rada ;
Mourcin, Frederic ;
Uhel, Fabrice ;
Pangault, Celine ;
Ruminy, Philippe ;
Dupre, Loic ;
Guirriec, Marion ;
Marchand, Tony ;
Fest, Thierry ;
Lamy, Thierry ;
Tarte, Karin .
BLOOD, 2015, 126 (16) :1911-1920
[6]  
[Anonymous], 2014, BLOOD, DOI DOI 10.1182/BLOOD.V124.21.802.802
[7]  
[Anonymous], BLOOD
[8]   Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial [J].
Ardeshna, Kirit M. ;
Qian, Wendi ;
Smith, Paul ;
Braganca, Nivette ;
Lowry, Lisa ;
Patrick, Pip ;
Warden, June ;
Stevens, Lindsey ;
Pocock, Christopher F. E. ;
Miall, Fiona ;
Cunningham, David ;
Davies, John ;
Jack, Andrew ;
Stephens, Richard ;
Walewski, Jan ;
Ferhanoglu, Burhan ;
Bradstock, Ken ;
Linch, David C. .
LANCET ONCOLOGY, 2014, 15 (04) :424-435
[9]   Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial [J].
Ardeshna, KM ;
Smith, P ;
Norton, A ;
Hancock, BW ;
Hoskin, PJ ;
MacLennan, KA ;
Marcus, RE ;
Jelliffe, A ;
Hudson, GV ;
Linch, DC .
LANCET, 2003, 362 (9383) :516-522
[10]   Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma [J].
Bachy, Emmanuel ;
Houot, Roch ;
Morschhauser, Franck ;
Sonet, Anne ;
Brice, Pauline ;
Belhadj, Karim ;
Cartron, Guillaume ;
Audhuy, Bruno ;
Ferme, Christophe ;
Feugier, Pierre ;
Sebban, Catherine ;
Delwail, Vincent ;
Maisonneuve, Herve ;
Le Gouill, Steven ;
Lefort, Sophie ;
Brousse, Nicole ;
Foussard, Charles ;
Salles, Gilles .
HAEMATOLOGICA, 2013, 98 (07) :1107-1114